SCHEMBL9923858

SCHEMBL9923858

CCOC(=O)N[C@H]1CC[C@H](N/C(=N\C(=O)c2ccc(F)c(F)c2)NCc2ccc(F)cc2F)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CHRM1 P11229 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
MAPT P10636 2/20 0.37
POLB P06746 1/20 0.37
RAB9A P51151 1/20 0.37
MCHR1 Q99705 5/20 0.37
EPHX2 P34913 1/20 0.36
CYP2C9 P11712 1/20 0.35
MAPK14 Q16539 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
KLKB1 P03952 1/20 0.35
TSHR P16473 1/20 0.35
CYP11B2 P19099 1/20 0.34
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923859 0.94 CHRM1 (0.41) ALDH1A1CHRM1SMN1; SMN2LMNAHTT
SCHEMBL9924065 0.92 P2RX7 (0.42) P2RX7
SCHEMBL9924064 0.92 CHRM1 (0.40) CHRM1SMN1; SMN2LMNAHTTMCHR1
SCHEMBL9924274 0.90 CHRM1 (0.41) ALDH1A1TDP1CHRM1MCHR1CYP2C9
SCHEMBL9924066 0.87 CHRM1 (0.41) ALDH1A1CHRM1SMN1; SMN2LMNAHTT
SCHEMBL9923856 0.87 CHRM1 (0.42) ALDH1A1CHRM1SMN1; SMN2LMNAHTT
SCHEMBL9924243 0.87 P2RX7 (0.39) ALDH1A1RAB9AMCHR1EPHX2MAPK14
SCHEMBL9923857 0.87 LMNA (0.40) CHRM1SMN1; SMN2LMNAHTTPOLB
SCHEMBL9923860 0.87 P2RX7 (0.40) ALDH1A1CHRM1SMN1; SMN2LMNARAB9A
SCHEMBL9924156 0.87 CHRM1 (0.45) ALDH1A1CHRM1MCHR1CYP2C9MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed